Sarah Boyce Avidity Biosciences, Inc. (RNA) insider trading activity

RNA Quotes by TradingView

Sarah Boyce is President and CEO of Avidity Biosciences, Inc.. Currently has a direct ownership of 305,871 shares of RNA, which is worth approximately $10.1 Million. The most recent transaction as insider was on Mar 12, 2024, when has been sold 28,000 shares (Common Stock) at a price of $1.24 per share, resulting in proceeds of $34,720. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 306K
9.35% 3M change
172.81% 12M change
Total Value Held $10.1 Million

Sarah Boyce Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 12 2024
BUY
Exercise of conversion of derivative security
$34,720 $1.24 p/Share
28,000 Added 16.66%
140,117 Common Stock
Mar 08 2024
SELL
Open market or private sale
$1,796,760 $21.39 p/Share
84,000 Reduced 42.83%
112,117 Common Stock
Mar 08 2024
BUY
Exercise of conversion of derivative security
$104,160 $1.24 p/Share
84,000 Added 29.99%
196,117 Common Stock
Mar 01 2024
SELL
Open market or private sale
$1,690,920 $20.13 p/Share
84,000 Reduced 42.83%
112,117 Common Stock
Mar 01 2024
BUY
Exercise of conversion of derivative security
$104,160 $1.24 p/Share
84,000 Added 29.99%
196,117 Common Stock
Jan 22 2024
SELL
Open market or private sale
$51,581 $10.13 p/Share
5,092 Reduced 10.37%
44,008 Common Stock
Jan 20 2024
BUY
Grant, award, or other acquisition
-
62,500 Added 48.18%
67,209 Common Stock
Feb 03 2023
SELL
Open market or private sale
$78,141 $24.26 p/Share
3,221 Reduced 5.69%
53,352 Common Stock
Feb 03 2023
BUY
Exercise of conversion of derivative security
$3,994 $1.24 p/Share
3,221 Added 5.39%
56,573 Common Stock
Feb 02 2023
SELL
Open market or private sale
$1,117,612 $24.36 p/Share
45,879 Reduced 46.23%
53,352 Common Stock
Feb 02 2023
BUY
Exercise of conversion of derivative security
$56,889 $1.24 p/Share
45,879 Added 31.62%
99,231 Common Stock
Feb 01 2023
SELL
Open market or private sale
$21,843 $24.27 p/Share
900 Reduced 1.66%
53,352 Common Stock
Feb 01 2023
BUY
Exercise of conversion of derivative security
$1,116 $1.24 p/Share
900 Added 1.63%
54,252 Common Stock
Jan 20 2023
BUY
Grant, award, or other acquisition
-
50,000 Added 48.38%
53,352 Common Stock
Aug 25 2022
SELL
Open market or private sale
$342,705 $23.07 p/Share
14,855 Reduced 100.0%
0 Common Stock
Aug 25 2022
BUY
Exercise of conversion of derivative security
$18,420 $1.24 p/Share
14,855 Added 50.0%
14,855 Common Stock
Aug 24 2022
SELL
Open market or private sale
$799,026 $22.8 p/Share
35,045 Reduced 100.0%
0 Common Stock
Aug 24 2022
BUY
Exercise of conversion of derivative security
$43,456 $1.24 p/Share
35,045 Added 50.0%
35,045 Common Stock
Aug 15 2022
SELL
Open market or private sale
$2,247 $22.47 p/Share
100 Reduced 100.0%
0 Common Stock
Aug 15 2022
BUY
Exercise of conversion of derivative security
$124 $1.24 p/Share
100 Added 50.0%
100 Common Stock

Also insider at

BLI
Berkeley Lights, Inc. Healthcare
Director
LGND
LIGAND PHARMACEUTICALS INC Healthcare
AHPAW
Avista Public Acquisition Corp. II Financial Services
Director
CTNM
Contineum Therapeutics, Inc.
Director
SB

Sarah Boyce

President and CEO
San Diego, CA

Track Institutional and Insider Activities on RNA

Follow Avidity Biosciences, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNA shares.

Notify only if

Insider Trading

Get notified when an Avidity Biosciences, Inc. insider buys or sells RNA shares.

Notify only if

News

Receive news related to Avidity Biosciences, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on RNA